Treating Diabetic Nephropathy — Are There Only Economic Issues?

Publisher Website
Google Scholar
Abstract
Economic issues sometimes seem to be the primary considerations in discussions of treatment for nephropathy in patients with type 2 diabetes. But in the end, the economics of treatment are driven by clinical issues, many of which have yet to be resolved. For example, in the United States, type 2 diabetes is the leading cause of end-stage renal disease; it accounted for approximately 40 percent of cases in patients who began dialysis between 1994 and 1999. Worse yet, the worldwide incidence of end-stage renal disease among patients with type 2 diabetes is expected to double by 2010. These depressing data . . .